PCSK9 and familial hyperaldosteronism: The ability of therapeutic MABs against PCSK9 to reduce the level of LDL-C in patients with homozygous FH and defective alleles of LDLR also demonstrates the possibility of a receptor-independent effect on LDL cholesterol [18].